Shaker R. Dakhil
- Oncology top 0.1%
- Cancer Treatment and Pharmacology 68
- Colorectal Cancer Treatments and Studies 61
- Lung Cancer Research Studies 30
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics 23
- Breast Cancer Treatment Studies 23
- Pathology and Forensic Medicine top 0.2%
- Lymphoma Diagnosis and Treatment 30
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations 57
- Genetics top 0.5%
- Estrogen and related hormone effects 31
- Co-authors
- Charles L. LoprinziPaul J. NovotnyJeff A. SloanKendrith M. RowlandNorman WolmarkRichard I. FisherTom R. FitchJames A. Mailliard
- Partner nations
- United StatesCanadaFrance
In The Last Decade
Shaker R. Dakhil
306 papers receiving 15.9k citations
Hit Papers
Peers
Comparison fields: 5 of 147
- Oncology 9.2k
- Cancer Research 3.1k
- Pathology and Forensic Medicine 3.0k
- Pulmonary and Respiratory Medicine 5.1k
- Genetics 1.4k
Countries citing papers authored by Shaker R. Dakhil
This map shows the geographic impact of Shaker R. Dakhil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shaker R. Dakhil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shaker R. Dakhil more than expected).
Fields of papers citing papers by Shaker R. Dakhil
This network shows the impact of papers produced by Shaker R. Dakhil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shaker R. Dakhil. The network helps show where Shaker R. Dakhil may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shaker R. Dakhil, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 7 | |
| 2 | 2024 | 1 | |
| 3 | 2023 | 1 | |
| 4 | 2022 | 0 | |
| 5 | 2021 | 22 | |
| 6 | 2018 | 33 | |
| 7 | 2018 | 10 | |
| 8 | Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trialbreakdown → | 2017 | 507 |
| 9 | 2013 | 32 | |
| 10 | 2012 | 123 | |
| 11 | 2012 | 111 | |
| 12 | 2012 | 92 | |
| 13 | 2012 | 43 | |
| 14 | 2009 | 127 | |
| 15 | 2009 | 52 | |
| 16 | 2008 | 26 | |
| 17 | 2008 | 402 | |
| 18 | 2006 | 86 | |
| 19 | 2006 | 58 | |
| 20 | 1992 | 41 |
About Shaker R. Dakhil
Shaker R. Dakhil is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 313 papers that have together received 16.4k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (68 papers), Colorectal Cancer Treatments and Studies (61 papers), Lung Cancer Treatments and Mutations (57 papers), Estrogen and related hormone effects (31 papers), Lymphoma Diagnosis and Treatment (30 papers), Lung Cancer Research Studies (30 papers), Cancer Genomics and Diagnostics (23 papers) and Breast Cancer Treatment Studies (23 papers). The work is most often cited by research in Oncology (9.2k citations), Cancer Research (3.1k citations) and Pathology and Forensic Medicine (3.0k citations). Shaker R. Dakhil has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Charles L. Loprinzi, Paul J. Novotny, Jeff A. Sloan, Kendrith M. Rowland, Norman Wolmark, Richard I. Fisher, Tom R. Fitch, James A. Mailliard, Julie R. Gralow and Patrick J. Flynn. Their work appears in journals such as New England Journal of Medicine, The Lancet and JAMA.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.